RMD vs PHG

For growth investors, ResMed Inc.

(RMD) is the stronger pick with 9. 8% revenue growth year-over-year, versus -1. 0% for Koninklijke Philips N. V. (PHG). ResMed Inc. (RMD) offers the better valuation at 22. 0x trailing P/E (19. 0x forward), making it the more compelling value choice. Analysts rate ResMed Inc. (RMD) a "Buy" — based on 35 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, ResMed Inc.

(RMD) is the cheapest at 22. 0x versus Koninklijke Philips N. V. at 24. 9x. On forward P/E, Koninklijke Philips N. V. is actually cheaper at 17. 6x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, ResMed Inc.

(RMD) delivered a total return of +13. 6%, compared to -41. 9% for Koninklijke Philips N. V. (PHG). Over 10 years, the gap is even starker: RMD returned +301. 1% versus PHG's +47. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), ResMed Inc.

(RMD) is the lower-risk stock at 0. 66β versus Koninklijke Philips N. V. 's 1. 12β — meaning PHG is approximately 70% more volatile than RMD relative to the S&P 500. On balance sheet safety, ResMed Inc. (RMD) carries a lower debt/equity ratio of 14% versus 74% for Koninklijke Philips N. V. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), ResMed Inc.

(RMD) is pulling ahead at 9. 8% versus -1. 0% for Koninklijke Philips N. V. (PHG). On earnings-per-share growth, the picture is similar: Koninklijke Philips N. V. grew EPS 224. 0% year-over-year, compared to 37. 4% for ResMed Inc.. Over a 3-year CAGR, RMD leads at 12. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

ResMed Inc.

(RMD) is the more profitable company, earning 27. 2% net margin versus 5. 0% for Koninklijke Philips N. V. — meaning it keeps 27. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: RMD leads at 32. 7% versus 8. 0% for PHG. At the gross margin level — before operating expenses — RMD leads at 59. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Koninklijke Philips N.

V. (PHG) trades at 17. 6x forward P/E versus 19. 0x for ResMed Inc. — 1. 4x cheaper on a one-year earnings basis.

All stocks in this comparison pay dividends.

Koninklijke Philips N. V. (PHG) offers the highest yield at 1. 5%, versus 1. 0% for ResMed Inc. (RMD).

For long-horizon retirement investors, ResMed Inc.

(RMD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 66), 1. 0% yield, +301. 1% 10Y return). Both have compounded well over 10 years (RMD: +301. 1%, PHG: +47. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.